HIGHLIGHTS
SUMMARY
Currently, the standard therapy for muscle-invasive bladder cancer (MIBC) is radical cystectomy with orthotopic neobladder substitution or other urinary diversion. Owing to the promising therapeutic progress made in recent years, patient-reported outcomes regarding radical cystectomy or bladder-sparing tri-modality therapy continues to be a concern for both patients and urologists, and deserves more investigation and surveillance. Although there are many studies reporting on the health-related quality of life (QOL) of bladder cancer patients, most of these were cross-sectional and may not be applicable for examining long-term effects. To . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.